[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obsessive-compulsive-disorder-in-adolescence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obsessive-compulsive-disorder-in-adolescence":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100486118","cbt-augmentation-to-promote-medication-discontinuation-in-pediatric-ocd-100486118",false,"NCT05609916","CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD","Inclusion Criteria:\n\n* The child is between the ages of 7 to 17 at enrollment with a primary diagnosis of OCD of \\> 6 months duration based on the Kiddie Schedule for Affective Disorders and Schizophrenia Lifetime Version for DSM-5 (KSADS-PL) and have a CY-BOCS ≥ 16.\n* The child is on stable and maximally tolerated SRI medication (i.e., clomipramine, fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram) for ≥12 weeks given that they are persistently and moderately symptomatic. Paroxetine is exclusionary due to safety concerns.\n* Both the child and parent participating in the study are English speaking.\n* Both the child and their parent participating in the study reside in Texas.\n\nExclusion Criteria:\n\n* The child has a diagnosis of lifetime DSM-5 bipolar disorder, psychotic disorder, and\u002For intellectual disability.\n* The child has severe current suicidal\u002Fhomicidal ideation and\u002For self-injury requiring medical intervention.\n* The child is receiving concurrent psychotherapy for OCD.\n* Initiation of a psychotropic medication less than 4 weeks prior to study enrollment or a stimulant\u002Fpsychoactive medication less than 2 weeks prior to study enrollment.","ALL","7 Years","17 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to examine whether youth with OCD who benefit from CBT augmentation to SRI can discontinue their medication without relapse over 24 weeks.",[26,27,28,29],"Cognitive Behavioral Therapy","Obsessive-Compulsive Disorder","Obsessive-Compulsive Disorder in Children","Obsessive-Compulsive Disorder in Adolescence","RECRUITING","2025-07-18",{"date":33,"type":34},"2025-07-20","ACTUAL",{"date":36,"type":34},"2022-11-30",{"date":38,"type":20},"2027-08-30",{"name":40,"class":41},"Baylor College of Medicine","OTHER"]